Topline Phase III pomalidomide data bolster Celgene's prospects in multiple myeloma
This article was originally published in Scrip
Celgene reported positive topline data on 23 October from a Phase III clinical trial for pomalidomide that could position the oral immunomodulatory agent well in the underserved multiple myeloma market after detailed results from the study, known as MM-003, are reported at a future medical conference.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.